Navigation Links
Novel Approach May Protect Against Heart Attack Injury
Date:7/10/2008

- Drugs Target Gene Pathways to Preserve Heart, Possibly Other Organs -

PHILADELPHIA, July 10 /PRNewswire-USNewswire/ -- Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects.

"Reduced blood flow, or ischemia, is a major problem in many organs, where it can lead to cell death and tissue damage," said study leader Peter J. Gruber, M.D., Ph.D., a cardiothoracic surgeon at Children's Hospital and a faculty member of the University of Pennsylvania School of Medicine. "We decided to look for a global approach to protecting heart tissue by inhibiting enzymes that govern how cells respond to ischemia."

Gruber's team published their findings online July 7 in the journal of the Federation of American Societies for Experimental Biology (FASEB). The article will appear in the journal's October 2008 print issue.

The researchers made use of drugs called histone deactylase (HDAC) inhibitors that alter the way DNA is packaged within cells, as well as modifying the function of other proteins. Building on previous work by other researchers, who showed that HDAC inhibitors reduce ischemic injury in the brain, they used the same agents in mice with induced heart damage.

"We found significant and dramatic results in the mice," said Gruber. "The HDAC inhibitors reduced the area of tissue injury, even when delivered an hour after the ischemic event occurred." The size of the myocardial infarction--an area of dead tissue caused by obstructed blood flow, as occurs after a heart attack--was reduced by more than half.

In further investigating how the HDAC inhibitors acted, Gruber's team found they blocked gene pathways that led to cell death and ischemia-induced vascular permeability, the leakage of fluid through blood vessels. They also identified a specific molecule, HDAC4, as the likely HDAC enzyme with the most critical role in affecting how cells respond to ischemia.

An important advantage of their finding, said Gruber, is that a number of HDAC inhibitors are already used in medicine, for treating both cancer and epilepsy, and are well-tolerated. Although much research remains to be done, he added, this raises the possibility that existing drugs, or modified versions of them, might play an important new role in heart disease.

Because the protective effect of HDAC inhibitors may occur even after the initial blockage of blood flow, therapies based on Gruber's research may lead to an emergency treatment following a heart attack. In addition, because open-heart surgery for both children and adults requires a period in which the heart is stopped, such treatment might also protect tissues from the adverse effects of interrupting blood flow during surgery.

For now, said Gruber, the next step for his study team will be to test how HDAC inhibitors work in protecting against ischemic injury in larger animals.

A National Institutes of Health grant partially supported the research, in addition to funding from the McCabe Foundation, the University Research Foundation and the Division of Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia.

Gruber's co-authors were Anne Granger, Ibrahim Abdullah, Faith Huebner, and Thomas Huebner, of Children's Hospital; and Jonathan A. Epstein, M.D., of the University of Pennsylvania School of Medicine. Gruber, Granger, and co-authors Andrea Stout and Tao Wang are members of the Penn Cardiovascular Institute, of which Epstein is the scientific director.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: John Ascenzi

Phone: (267) 426-6055

Ascenzi@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
2. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
3. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
4. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
5. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
6. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
7. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
10. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
11. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent Medical, ... Aufnahme von Patienten für eine Studie zur Sicherheit ... („WEB") speziell für die Behandlung von rupturierten intrakraniellen ... MD, Leiter der Neuroradiologie an der Universitätsklinik Bicètre ... Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Los Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... be. With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz ... there, she dedicated herself to meditation for its impact on her life, implementing a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in ... of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration ... to their small and medium business (SMB) clients. , In recent ...
(Date:2/12/2016)... ... ... The Jones Agency, a family owned insurance company with offices serving Arlington, ... drive with the Tarrant Area Food Bank in the hopes of alleviating hunger for ... the Tarrant County Food Bank offers hope and security to the one in six ...
(Date:2/12/2016)... ... , ... Donor Network West, the organ procurement organization that heals lives through ... Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific organ ... more certain time frame for donor families for the recovery of organs. , ...
Breaking Medicine News(10 mins):